Tonghua Dongbao Pharmaceutical (600867) Stock Overview
Researches and develops, manufactures, and sells pharmaceutical for the treatment of diabetes, endocrine, and cardiovascular and cerebrovascular diseases products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
600867 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Tonghua Dongbao Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥8.43 |
| 52 Week High | CN¥9.64 |
| 52 Week Low | CN¥7.00 |
| Beta | 0.25 |
| 1 Month Change | 5.77% |
| 3 Month Change | 12.55% |
| 1 Year Change | 4.07% |
| 3 Year Change | -11.26% |
| 5 Year Change | -40.00% |
| Change since IPO | 871.89% |
Recent News & Updates
Recent updates
Is Tonghua Dongbao Pharmaceutical (SHSE:600867) Using Too Much Debt?
Feb 21
Investors Appear Satisfied With Tonghua Dongbao Pharmaceutical Co., Ltd.'s (SHSE:600867) Prospects
Jan 02Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Pretty Healthy Balance Sheet
Oct 22Tonghua Dongbao Pharmaceutical Co., Ltd.'s (SHSE:600867) Earnings Haven't Escaped The Attention Of Investors
Sep 30Some May Be Optimistic About Tonghua Dongbao Pharmaceutical's (SHSE:600867) Earnings
Sep 06Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Analysts Just Slashed This Year's Estimates
Sep 05Calculating The Intrinsic Value Of Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867)
Aug 22Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Rock Solid Balance Sheet
Jun 19Improved Earnings Required Before Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Shares Find Their Feet
May 23Shareholder Returns
| 600867 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -1.1% | -1.6% | 1.9% |
| 1Y | 4.1% | 35.0% | 34.9% |
Return vs Industry: 600867 underperformed the CN Pharmaceuticals industry which returned 35% over the past year.
Return vs Market: 600867 underperformed the CN Market which returned 34.9% over the past year.
Price Volatility
| 600867 volatility | |
|---|---|
| 600867 Average Weekly Movement | 2.7% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in CN Market | 8.4% |
| 10% least volatile stocks in CN Market | 2.8% |
Stable Share Price: 600867 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600867's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 3,410 | Chun Sheng Leng | www.thdb.com |
Tonghua Dongbao Pharmaceutical Co., Ltd. researches and develops, manufactures, and sells pharmaceutical for the treatment of diabetes, endocrine, and cardiovascular and cerebrovascular diseases products in China. It offers human insulin API and injections; insulin glargine API and injections; insulin aspart API and injections; liraglutide injections; zhennaoning capsules; and diabetes-related medical devices. The company also provides insulin pen and needle injection system, blood sugar monitoring system, and online and offline patient management system.
Tonghua Dongbao Pharmaceutical Co., Ltd. Fundamentals Summary
| 600867 fundamental statistics | |
|---|---|
| Market cap | CN¥16.38b |
| Earnings (TTM) | -CN¥148.24m |
| Revenue (TTM) | CN¥2.07b |
Is 600867 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600867 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.07b |
| Cost of Revenue | CN¥621.25m |
| Gross Profit | CN¥1.45b |
| Other Expenses | CN¥1.60b |
| Earnings | -CN¥148.24m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 26, 2025
| Earnings per share (EPS) | -0.076 |
| Gross Margin | 69.98% |
| Net Profit Margin | -7.16% |
| Debt/Equity Ratio | 12.1% |
How did 600867 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/11 07:54 |
| End of Day Share Price | 2025/08/08 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tonghua Dongbao Pharmaceutical Co., Ltd. is covered by 23 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yanyin Zhu | China International Capital Corporation Limited |
| Bing Zhao | China Renaissance Securities |
| Tan Huan Gan | Citic Securities Co., Ltd. |